Elevai Labs, Inc. Common Stock (ELAB)vsBeiGene, Ltd. (ONC)
ELAB
Elevai Labs, Inc. Common Stock
$0.95
+7.88%
HEALTHCARE · Cap: $5.09M
ONC
BeiGene, Ltd.
$322.08
-1.57%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 451059% more annual revenue ($5.74B vs $1.27M). ONC leads profitability with a 8.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).
ELAB
Avoid25
out of 100
Grade: F
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ELAB.
Margin of Safety
+81.1%
Fair Value
$1857.02
Current Price
$322.08
$1534.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ELAB
The strongest argument for ELAB centers on Price/Book.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : ELAB
The primary concerns for ELAB are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
ELAB profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.49 — expect wider price swings.
ONC is growing revenue faster at 35.5% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 25/100) and 35.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elevai Labs, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Elevai Labs, Inc. (Ticker: ELAB) is a cutting-edge technology company specializing in artificial intelligence and machine learning solutions, primarily serving the healthcare and finance sectors. With a focus on sophisticated data analytics, Elevai Labs equips organizations with the tools to derive actionable insights from complex datasets, driving operational efficiencies and informed decision-making. Positioned strategically in a rapidly evolving tech landscape, the company is well-equipped to capitalize on emerging market trends, creating significant value for its clients and stakeholders. Elevai Labs' dedication to advancing AI technologies establishes it as a key player with promising potential for sustainable growth and competitive differentiation.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?